Implications of a Reduction in the Hemoglobin Target in Erythropoiesis-Stimulating Agent-Treated Hemodialysis Patients

BACKGROUND: Patients treated with erythropoiesis-stimulating agents (ESAs) to a hemoglobin (Hb) level >12.0 g/dl have increased risk of multiple complications, including death. The optimal Hb target for ESA use has not been established. We hypothesized that reducing the target Hb would prevent le...

Descripción completa

Detalles Bibliográficos
Autores principales: Nguyen, Timothy V., Goldfarb, David S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2011
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3290836/
https://www.ncbi.nlm.nih.gov/pubmed/22470394
http://dx.doi.org/10.1159/000334228

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3290836/
https://www.ncbi.nlm.nih.gov/pubmed/22470394
http://dx.doi.org/10.1159/000334228

Ejemplares similares